Teligent, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Timothy Sawyer
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 105 Lincoln Avenue Buena NJ United States of America 08310
- IPO Date
- Jul 30, 1981
- CIK
- 0000352998
- Website
- teligent.com
- Similar Companies
- Business
- Teligent, Inc. (TLGT) is a specialty generic pharmaceutical company that develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products primarily in the United States and Canada; its core offerings include topical formulations such as creams (Synalar, Spectazole), lotions (Kenalog), ointments (Topicort, Kenalog), and solutions (Pennsaid, Xylocaine), alongside hospital-based sterile injectables like cephalosporins (Cefotan, Fortaz, Zinacef) and other molecules; the company also provides contract development, manufacturing, filling, and packaging services for semi-solid and liquid products to pharmaceutical, over-the-counter (OTC), and cosmetic markets. Founded in 1977 and headquartered at 105 Lincoln Avenue, Buena, New Jersey, Teligent operates through segments focused on high-barrier dosage forms, targeting hospitals, clinics, pharmacists, and branded/generic customers with generic equivalents to original brands like Diclofenac (alternative to Pennsaid). In October 2021, the company filed for voluntary Chapter 11 bankruptcy protection in Delaware amid FDA warning letters for manufacturing violations at its Buena facility, debt exceeding $130 million, and COVID-19 impacts, securing $12 million in debtor-in-possession financing and initiating asset sales; in January 2022, Hikma Pharmaceuticals completed the acquisition of its Canadian assets for $45.75 million, including 25 sterile injectables, three ophthalmic products, and a pipeline of seven items (four Health Canada-approved), marking Hikma's entry into the Canadian injectables market; Teligent ceased operations via Chapter 11 liquidation on July 26, 2022, with ongoing 2025 litigation by its bankruptcy administrator alleging former directors and officers breached oversight duties on FDA compliance failures that precipitated the collapse.
TLGT Stock: Why The Price Substantially Fell
Top Penny Stocks to Buy Right Now? 3 to Check Out This Month
Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2021 Results - Earnings Call Transcript
Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update
Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders
Trading Biotech Penny Stocks? Check These 3 Out
Teligent's (TLGT) CEO Tim Sawyer on Q1 2021 Results - Earnings Call Transcript
Teligent: Q1 Earnings Insights
Teligent, Inc. to Hold Conference Call for First Quarter 2021 Financial Results on Tuesday May 25, 2020
Teligent, Inc. Announces 2020 Year-End Earnings Report and Provides Business Update
Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors
Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule
Teligent, Inc. Announces Third Quarter 2020 Results
Teligent: 7 Things for Investors to Know About TLGT Stock
Why Is It Moving? Analyzing The Upward Movement in Teligent's Stock Today
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses to Contact the Firm